Patient Recruitment Discontinued in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in NSCLC September 18, 2024
First patient enrolled in triple combination arm of BI-1206, rituximab and Calquence® for the treatment of NHL September 18, 2024
Global Launch of Artemia Ph 3 Registration Study for Cancer Vaccine Tedopi® in 2L NSCLC Cancer Announced September 18, 2024
Trials evaluating ONCT-534 in metastatic CRPC & ONCT-808 in BCL discontinued to explore strategic alternative September 18, 2024
First patient dosed in Investigator-initiated Ph Ib study of iadademstat in 1L AML September 18, 2024
IDMC recommends continuing Ph 3 trial (IOB-013/KN-D18) of IO102-IO103 following a per-protocol interim analysis September 10, 2024
GBM program of INB-200 and INB-400 to be suspended; AML program of INB-100 to be prioritized September 10, 2024
First patient enrolled in Ph 3 SOHO-02 trial of BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations September 3, 2024
Enrollment Completed in Ph 2 I-SPY 2 Arm Evaluating Lasofoxifene in Neoadjuvant Breast Cancer Setting September 3, 2024
Nadunolimab clinical trials in AML/MDA and TNBC to be initiated in Q4 2024 and H2 2025, respectively September 3, 2024
FAILED TRIAL: PRECISION1 trial of nab-sirolimus in patients with solid tumors with TSC1/2 inactivating mutations to be halted as study unlikely to exceed the efficacy threshold August 27, 2024
Randomized controlled trial of Nana-val in EBV-positive PTCL patients planned to begin in the second half of 2025 to support potential registration August 27, 2024
First patient dosed in trial of MOMA-313 in patients with cancers carrying mutations in DNA repair genes August 27, 2024
Enrollment Completed in China GC/GEJ Pivotal Ph 2 Clinical Trial of Claudin18.2 CAR T (Satri-cel) August 27, 2024
First Patient dosed in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer August 27, 2024
Ph 1a/1b trial of OMX-040 in patients with advanced solid tumors advanced to expansion phase in kidney cancer and angiosarcoma August 27, 2024
